Rheumatology Network Newsletter

To view this email as a web page, click here.

New JAK Inhibitor Approved for Rheumatoid Arthritis

AbbVie announced on Friday that the Food and Drug Administration has approved the oral once-daily JAK inhibitor Rinvoq (upadacitinib) for the treatment of adults with moderate to severe active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.

RA Treatments Work, but Raise Infection Risk

Both TNF inhibitors and non-TNFi biologic DMARDs increase the risk of serious infection in rheumatoid arthritis patients compared to conventional synthetic DMARDs. Despite the risk, the treatments are effective in reducing disease activity, researchers report.

Review: RA Mobile Apps, the Top 19

A scientific review of mobile apps for tracking rheumatoid arthritis disease activity finds that most apps are either simple calculators for physicians to measure disease activity or tools for patients to track symptoms, most of which do not uniformly collect data using validated instruments or composite disease activity measures.

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.